1. Adelaide Research & Scholarship

Search


Current filters:






Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-5 of 5 (Search time: 0.001 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2015Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non–small-cell lung cancerRamalingam, S.S.; Shtivelband, M.; Soo, R.A.; Barrios, C.H.; Makhson, A.; Segalla, J.G.; Pittman, K.B.; Kolman, P.; Pereira, J.R.; Srkalovic, G.; Belani, C.P.; Axelrod, R.; Owonikoko, T.K.; Qin, Q.; Qian, J.; McKeegan, E.M.; Devanarayan, V.; McKee, M.D.; Ricker, J.L.; Carlson, D.M.; et al.
2013Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.Siu, L.; Shapiro, J.; Jonker, D.; Karapetis, C.; Zalcberg, J.; Simes, J.; Couture, F.; Moore, M.; Price, T.; Siddiqui, J.; Nott, L.; Charpentier, D.; Liauw, W.; Sawyer, M.; Jefford, M.; Magoski, N.; Haydon, A.; Walters, I.; Ringash, J.; Tu, D.; et al.
2012Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: Results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialArdizzoni, A.; Tiseo, M.; Boni, L.; Vincent, A.; Passalacqua, R.; Buti, S.; Amoroso, D.; Camerini, A.; Labianca, R.; Genestreti, G.; Boni, C.; Ciuffreda, L.; Di Costanzo, F.; De Marinis, F.; Crino, L.; Santo, A.; Pazzola, A.; Barbieri, F.; Zilembo, N.; Colantonio, I.; et al.
2015A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinomaPal, S.; Azad, A.; Bhatia, S.; Drabkin, H.; Costello, B.; Sarantopoulos, J.; Kanesvaran, R.; Lauer, R.; Starodub, A.; Hauke, R.; Sweeney, C.; Hahn, N.; Sonpavde, G.; Richey, S.; Breen, T.; Kremmidiotis, G.; Leske, A.; Doolin, E.; Bibby, D.; Simpson, J.; et al.
2018Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk diseaseBranford, S.; Wang, P.; Yeung, D.T.; Thomson, D.; Purins, A.; Wadham, C.; Shahrin, N.H.; Marum, J.E.; Nataren, N.; Parker, W.T.; Geoghegan, J.; Feng, J.; Shanmuganathan, N.; Mueller, M.C.; Dietz, C.; Stangl, D.; Donaldson, Z.; Altamura, H.; Georgievski, J.; Braley, J.; et al.

Discover